LIVZON PHARMA

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1985-01-26

Employees: 8.9K

Market Cap: -

Website: http://www.livzon.com.cn

Introduction: The company was founded in January 1985. It is a comprehensive pharmaceutical group company integrating R&D, production and sales of pharmaceutical products, and is an A+H listed company. The company regards R&D innovation as the cornerstone of sustainable development, and continues to pay attention to new molecules and cutting-edge technologies in the globa...

Clinical Trials

A Study to Evaluate the Efficacy and Safety of LZM012

Phase 3

Recruiting

Conditions: Psoriasis

Interventions: Biological: LZM012
Biological: Secukinumab

First Posted Date: 2023-11-01

Last Posted Date: 2023-11-01

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 918

Registration Number: NCT06110676

Locations: 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

Phase 3

Completed

Conditions: Stress Ulcer Bleeding

Interventions: Drug: Ilaprazole Sodium
Drug: Esomeprazole 40mg
Drug: Placebo 2
Drug: Placebo 1

First Posted Date: 2023-05-03

Last Posted Date: 2023-05-03

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 449

Registration Number: NCT05841394

Locations: 🇨🇳
Shanghai Jiaotong University Affiliate Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳
The First Affiliated Hopspital of Xinjiang Medical University, Urumchi, Xinjiang, China

A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5

Early Phase 1

Active, not recruiting

Conditions: COVID-19 Pandemic

Interventions: Biological: V-01
Biological: V-01-351/V-01-B5
Biological: V-01/V-01-B5

First Posted Date: 2022-10-19

Last Posted Date: 2022-11-07

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 48

Registration Number: NCT05585567

Locations: 🇨🇳
Shaoguan Hospital of Chinese Medicine, Shaoguan, Guangdong, China

Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

Early Phase 1

Active, not recruiting

Conditions: COVID-19 Pandemic

Interventions: Biological: V-01D-351
Biological: CoronaVac

First Posted Date: 2022-10-17

Last Posted Date: 2022-10-19

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 40

Registration Number: NCT05583357

Locations: 🇨🇳
Shaoguan Hospital of Chinese Medicine, Shaoguan, Guangdong, China

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

Phase 2

Conditions: COVID-19 Pandemic

Interventions: Biological: Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine

First Posted Date: 2022-03-10

Last Posted Date: 2022-03-10

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 20

Registration Number: NCT05273528

Locations: 🇨🇳
Shaoguan Hospital of Chinese Medicine, Shaoguan, Guangdong, China

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity

Phase 2

Conditions: COVID-19 Pandemic

Interventions: Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine

First Posted Date: 2022-02-15

Last Posted Date: 2022-03-03

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 34

Registration Number: NCT05239832

Locations: 🇨🇳
The Fifth Peoples' Hospital of Zhuhai, Zhuhai, Guangdong, China

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine

Phase 2

Conditions: COVID-19 Pandemic

Interventions: Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
Biological: SARS-Cov-2 Vaccine Inactivated

First Posted Date: 2022-02-14

Last Posted Date: 2022-03-29

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 150

Registration Number: NCT05238649

Locations: 🇨🇳
Zhuhai Peoples' Hospital Medical Group, Zhuhai, Guangdong, China

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization

Not Applicable

Conditions: COVID-19 Pandemic

Interventions: Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine

First Posted Date: 2021-11-18

Last Posted Date: 2021-11-18

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 45

Registration Number: NCT05125874

Locations: 🇨🇳
Zhuhai Peoples' Hospital Medical Group, Zhuhai, Guangdong, China

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Phase 3

Active, not recruiting

Conditions: COVID-19 Pandemic

Interventions: Biological: Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
Other: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

First Posted Date: 2021-10-27

Last Posted Date: 2023-04-25

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 22500

Registration Number: NCT05096845

Locations: 🇵🇭
Mary Mediatrix Medical Center, Lipa city, Batangas, Philippines
🇷🇺
Central Clinical Hospital of the Russian Academy of Sciences, Engels, Russian Federation
🇵🇭
Makati Medical Center, Makati City, Philippines

and more 22 locations

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study

Phase 3

Completed

Conditions: COVID-19 Pandemic

Interventions: Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
Biological: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

First Posted Date: 2021-10-27

Last Posted Date: 2023-04-25

Lead Sponsor: Livzon Pharmaceutical Group Inc.

Target Recruit Count: 10381

Registration Number: NCT05096832

Locations: 🇲🇾
Sarawak General Hospital, Kuching, Sarawak, Malaysia
🇲🇾
Sunway Medical Centre (SunMed), Petaling Jaya, Malaysia
🇲🇾
Seri Manjung Hospital, Seri Manjung, Malaysia

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy